PHVS (Pharvaris NV) Net Profit

PHVS (Pharvaris) - company brandmark

The value of Pharvaris N.V. (PHVS) is driven by success in drug development rather than market cycles, with macroeconomic influence limited to the availability of capital for research. The company's revenues are based on bringing therapies for the treatment of hereditary angioedema to market. The business operates in an autonomous cycle, remaining a defensive asset. The market trend for share value with the -0.20 indicator is shown below.

PHVS (Pharvaris N.V.) Net Profit history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Pharvaris (PHVS)

- price and consensus price forecast:
Stock Quotes Pharvaris Pharma|PHVS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Pharvaris Pharma|PHVS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Pharvaris|PHVS - Book Capitalization|Market Capitalization to Book Value pharvaris.com|PHVS - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Pharvaris N.V.|PHVS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Pharvaris NV|PHVS - Company Total Debt|Debts to Book Capitalization Pharvaris Pharma|PHVS - Company Long-Term Debt|Company Short-Term Indebtedness Pharvaris|Immediate Liquidity pharvaris.com
- net income and valuation multiples indicators:
PHVS - Company Net Income
Summary company analysis:Pharvaris N.V.
Core merchandise of Pharvaris Corp

Investors must protect their capital from volatility by identifying points of true business resilience. Pharvaris N.V. (PHVS) is expanding its market and increasing margins by transitioning to oral drug formulations, creating a foundation for growth. By analyzing the company's profit, we observe the real dynamics of net earnings without the smoothing effect of quarterly reports. This metric reveals liquidity management efficiency and the cost of servicing obligations. The stable trend of this indicator confirms the asset's reliability for a long-term portfolio.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|AbCellera Biologics Inc. - Company Profit|Net Profit TRML (Tourmaline Bio)|Precigen Inc (PGEN) - Company Net Income|PHAR - Company Net Income|Profit After Tax NKTR|UPB: Net Profit|zenasbio.com - Final Profit|IMNM (Immunome) - Net Profit|Net Profit Gossamer Bio Inc|Company Net Income KalVista Pharmaceuticals Inc (KALV)|SEPN (Septerna Pharma) - Final Profit|Pieris Pharmaceuticals - Net Income|savarapharma.com - Company Net Income|Rigel Pharmaceuticals, Inc. - Net Profit|ANAB - Net Profit|Astria Pharma (ATXS) - Company Net Income|enGene Corp - Final Profit|RAPT (RAPT Therapeutics, Inc.) - Net Profit|Aerovate (JBIO) - Net Financial Result|Company Net Income Aclaris Therapeutics, Inc. (ACRS)|Net Financial Result Kyverna Therapeutics Inc.|Tiziana Life Sciences PLC - Net Income|Final Profit CABA|VTYX - Company Net Income|THTX (theratech.com) - Company Profit|AVTX (Avalo Therapeutics) - Net Income|ELDN - Net Financial Result|Net Income AGEN|Company Net Income CLYM|Net Income ZURA (Zura Bio Limited)|Net Financial Result atyrpharma.com|Company Net Income Adagene Inc. ADAG|IMA (ImageneBio) - Profit After Tax|Shattuck Therapeutics - Net Profit|Final Profit EQ (Equillium, Inc.)|CNTB (connectbiopharm.com) - Net Income|IMUX (Immunic) - Company Net Income|Company Net Income Atara Biotherapeutics, Inc.|InflaRx GmbH (IFRX) - Net Financial Result|Company Net Income X4 Pharma (XFOR)|ACET: Profit After Tax|Net Profit CELU (Celularity)|Final Profit INMB|Barinthus Biotherapeutics plc - Net Profit|KZR - Net Profit|SAB Biotherapeutics, Inc (SABS) - Company Net Income|Akari Therapeutics, Plc - Final Profit|Company Net Income Enlivex Therapeutics Ltd|Net Income Q32 Bio Corp (QTTB)|Net Profit GOVX|Net Profit Edesa Biotech Inc (EDSA)|iBio Corp - Net Income|Final Profit CARM|XTL Biopharmaceuticals - Net Profit|Net Financial Result Bolt Biotherapeutics BOLT|hcwbiologics.com (HCWB) - Company Net Income|Net Income Aptevo Therapeutics Inc.|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Net Income GRI (GRI Bio, Inc.)|Net Profit xortx.com (XRTX)|Company Net Income Vyome Holdings HIND|REVB: Company Profit|Indaptus - Net Profit|Company Net Income BiondVax Pharmaceuticals|calcimedica.com (CALI) - Company Net Income|Profit After Tax AFMD (Affimed N.V.)|ALLK (Allakos Inc) - Net Profit|HOOK: Final Profit|Net Profit IGMS|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|Final Profit TCBP|THRD: Net Income